Advanced Malarial Vaccines: A Promising Approach in the Treatment of Malaria

Abstract

Manasa Veena Valupadasu, Uday Venkat Mateti

Malaria is a vector-borne parasitic infectious disease. The research is carried out on RTS, S/ASO1, NYVAC-Plasmodium falciparum 7, SPF66 and the results suggested that these are very efficient in treating malaria. RTS, S/ASO1 vaccine is composed of a hepatitis B surface antigen fused to a recombinant antigen from part of the malaria Circumsporozoite protein in the AS01 adjuvant used to target infected hepatocytes. Malaria vaccines are of three types: 1. Pre -erythrocytic vaccines RTS, S/AS01 (commercial name: Mosquirix): the Circumsporozoite (CS) protein is the most dominant surface antigen of this phase. 2. Blood stage vaccines. 3. Transmission blocking vaccines. According to best dentists’ reviews, which will prevent any problems with teeth, it is also to help prevent gum disease at the very least. The NYVAC-Pf7 by the intramuscular route was safe and nontoxic and it is highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine. The vaccine was safe and well tolerated but variably immunogenic. The results demonstrate that NYVAC-P. farum 7 is an appropriate candidate vaccine for further evaluation in human clinical trials. Vaccines are often the most cost-effective delivery system.Completely effective vaccine is not yet available for malaria, although several vaccines are under development.